Physician profile

Long Duc Tran

Nephrology (Internal Medicine) · Dallas, TX

NPI 1306895024

$2,757.11

in general payments reported to CMS, 2019-2025

34 companies · $681 in 2025

The $681 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,530.81
Education$2.62

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals Lp $584.04 2019-2025 Farxiga, Lokelma
Amgen INC. $254.44 2023-2025 Tavneos, Krystexxa
Akebia Therapeutics INC $150.45 2019-2020
Novo Nordisk INC $143.35 2022-2025 Ozempic, Rybelsus
Vifor Pharma, INC. $125.32 2019-2023 Veltassa
Opko Pharmaceuticals, LLC $120.87 2019-2025 Rayaldee
Glaxosmithkline, LLC. $114.99 2022-2024 Benlysta
Mallinckrodt Hospital Products INC. $112.73 2020-2023 Acthar
Otsuka America Pharmaceutical, INC. $108.43 2019-2025 Jynarque
Horizon Therapeutics Plc $94.14 2023 Krystexxa
Fresenius USA Marketing, INC. $87.28 2022-2025 Velphoro
Scpharmaceuticals INC. $85.04 2025
Bayer Healthcare Pharmaceuticals INC. $73.75 2023-2025
Shire North American Group INC $65.42 2019
La Jolla Pharmaceutical Company $63.22 2019
Show all 34 companies
CompanyGeneral paymentsYearsTop products
Travere Therapeutics, INC. $56.28 2023-2024
Boehringer Ingelheim Pharmaceuticals, INC. $54.67 2024-2025 Jardiance
Alexion Pharmaceuticals, INC. $46.53 2023 Ultomiris
Janssen Pharmaceuticals, INC $45.96 2019-2021
Aurinia Pharma U.S., INC. $41.61 2024 Lupkynis
Calliditas Therapeutics US INC. $36.43 2025 Tarpeyo
Genentech USA, INC. $33.28 2019
Nxstage Medical, INC. $31.16 2022
Ardelyx, INC. $27.55 2025 Ibsrela
Ani Pharmaceuticals, INC. $24.85 2023 Purified Cortrophin Gel
Melinta Therapeutics, LLC $24.70 2019
Genzyme Corporation $24.46 2019
Veloxis Pharmaceuticals, INC. $22.63 2022
Takeda Pharmaceuticals U.S.A., INC. $21.23 2024 Livtencity
Mallinckrodt Enterprises LLC $19.91 2019
Lilly USA, LLC $18.97 2025 Jardiance
Smith+Nephew, INC. $14.77 2024 Oasis, Grafix Pl
Chiesi USA, INC. $14.38 2019
Getinge USA Sales, LLC $14.27 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Long Duc Tran

$2,757.11

in general payments reported 2019-2025

Years
2019-2025
Top company
Astrazeneca Pharmaceuticals Lp
Context
The $681 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).

https://glasscript.com/doctor/13359/long-duc-tran

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.